Drugs / MK-0616A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300280 | Dec 2025 → Oct 2026 expected | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0616A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300280 ↗ |
| Route | Oral | “oral tablets” NCT07300280 ↗ |